Prior to the routine use of antifungal prophylaxis in CGD, a randomized placebo-controlled study showed that the addition of interferon-gamma (IFNγ) decreased serious infections by about two thirds, and so many centers use IFNγ in addition to TMP/SMX and itraconazole (7). This evidence concerns the gene IFNG and chronic granulomatous disease.